BeOne Medicines (ONC) Accumulated Expenses (2015 - 2026)

BeOne Medicines (ONC) has reported Accumulated Expenses for 12 consecutive years, with $1.3 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Accumulated Expenses rose 39.1% year-over-year to $1.3 billion in Q2 2026; TTM through Jun 2026 was $1.3 billion, a 39.1% increase from a year earlier, with the FY2025 full-year figure at $1.1 billion, up 38.0% from the prior year.
• Accumulated Expenses was $1.3 billion for Q2 2026 at BeOne Medicines, up from $1.1 billion in the prior quarter.
• Over five years, Accumulated Expenses peaked at $1.3 billion in Q2 2026 and troughed at $386.0 million in Q1 2022.
• A 5-year average of $699.0 million and a median of $669.4 million in 2024 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses dropped 16.25% in 2022 and soared 55.93% in 2026, its largest moves.
• Over 5 years, Accumulated Expenses stood at $467.4 million in 2022, then surged by 48.44% to $693.7 million in 2023, then climbed by 15.85% to $803.7 million in 2024, then surged by 38.0% to $1.1 billion in 2025, then increased by 13.99% to $1.3 billion in 2026.
• The last three Accumulated Expenses figures came in at $1.3 billion (Q2 2026), $1.1 billion (Q1 2026), and $1.1 billion (Q4 2025), per Business Quant data.